Cherry Tree Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cherry Tree Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$670	Hold	2	–	–	﹤0.01%	555
2025 Q4	$681	Sell	2 -10	-83%	-$4.31K	﹤0.01%	561
2025 Q3	$4.5K	Hold	12	–	–	﹤0.01%	479
2025 Q2	$5.12K	Hold	12	–	–	﹤0.01%	472
2025 Q1	$5.58K	Hold	12	–	–	﹤0.01%	514
2024 Q4	$4.63K	Hold	12	–	–	﹤0.01%	481
2024 Q3	$5.35K	Hold	12	–	–	﹤0.01%	477
2024 Q2	$5.39K	Hold	12	–	–	﹤0.01%	456
2024 Q1	$4.81K	Hold	12	–	–	﹤0.01%	442
2023 Q4	$4.68K	Hold	12	–	–	﹤0.01%	436
2023 Q3	$4K	Hold	12	–	–	﹤0.01%	429
2023 Q2	$4.05K	Buy	+12	New	+$4.04K	﹤0.01%	431

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cherry Tree Wealth Management's VRTX Position: Q1 2026 in Review

Cherry Tree Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 2 shares worth $670. The position accounts for ﹤0.01% of the portfolio, ranked #555.

Cherry Tree Wealth Management first reported a position in VRTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $5.58K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Cherry Tree Wealth Management held 2 shares of Vertex Pharmaceuticals worth $670 as of Q1 2026.
Cherry Tree Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Cherry Tree Wealth Management's portfolio in Q1 2026, its #555 holding.
Cherry Tree Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Cherry Tree Wealth Management's Vertex Pharmaceuticals position peaked at $5.58K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cherry Tree Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.